- Home
- DOYU vs NYXH Comparison
DOYU vs NYXH Comparison
Compare DOYU & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOYU | NYXH |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | China | Belgium |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.0M | 161.9M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DOYU | NYXH |
|---|---|---|
| Price | $4.59 | $1.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $9.33 |
| AVG Volume (30 Days) | 31.2K | ★ 501.1K |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.28 | $1.26 |
| 52 Week High | $9.34 | $8.59 |
Technical Indicators
Market Signals| Indicator | DOYU | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 39.95 | 35.28 |
| Support Level | $4.41 | $1.26 |
| Resistance Level | $4.98 | $1.70 |
| Average True Range (ATR) | 0.18 | 0.16 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 13.08 | 88.89 |
Price Performance
Historical ComparisonAbout DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.